Recent meta-analyses of randomized controlled trials have provided evidence supporting the efficacy of SGLT2 inhibitors in improving hepatic steatosis and fibrosis in MASLD patients, with consistent benefits observed across different agents within the class [21,22]. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatotic liver disease.